Mortality in the highly active antiretroviral therapy era - Changing causes of death and disease in the HIV outpatient study

被引:1104
作者
Palella, Frank J., Jr.
Baker, Rose K.
Moorman, Anne C.
Chmiel, Joan S.
Wood, Kathleen C.
Brooks, John T.
Holmberg, Scott D.
机构
[1] Northwestern Univ, Feinberg Sch Med, Div Infect Dis, Chicago, IL 60611 USA
[2] Cerner Corp, Vienna, VA USA
[3] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA
关键词
mortality; opportunistic infection; liver; cause of death; trends; HAART;
D O I
10.1097/01.qai.0000233310.90484.16
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: AIDS-related death and disease rates have declined in the highly active antiretroviral therapy (HAART) era and remain low; however, current causes of death in HAART-treated patients remain ill defined. Objective: To describe mortality trends and causes of death among HIV-infected patients in the HAART era. Design: Prospective, multicenter, observational cohort study of participants in the HIV Outpatient Study who were treated froth January 1996 through December 2004. Measurements: Rates of death, opportunistic disease, and other non-AIDS-defining illnesses (NADIs) determined to be primary or secondary causes of death. Results: Among 6945 HIV-infected patients followed for a median of 39.2 months, death rates fell from 7.0 deaths/100 person-years of observation in 1996 to 1.3 deaths/100 person-years in 2004 (P= 0.008 for trend). Deaths that included AIDS-related causes decreased from 3.79/100 person-years in 1996 to 0.32/100 person-years in 2004 (P= 0.008). Proportional increases in deaths involving liver disease, bacterenua/sepsis, gastrointestinal disease, non-AIDS malignancies, and renal disease also occurred (P=< 0.001, 0.017. 0.006, < 0.001, and 0.037. respectively.) Hepatic disease was the only reported cause of death for which absolute rates increased over time, albeit not significantly, from 0.09/100 person-years in 1996 to 0.16/100 person-years in 2004 (P = 0.10). The percentage of deaths due exclusively to NADI rose from 13.1% in 1996 to 42.5% in 2004 (P < 0.001 for trend), the most frequent of which were cardiovascular, hepatic, and pulmonary disease, and non-AIDS malignancies in 2004. Mean CD4 cell counts closest to death (n=486 deaths) increased froth 59 cells/mu L in 1996 to 287 cells/mu L in 2004 (P < 0.001 for trend). Patients dying of NADI causes were more HAART experienced and initiated HAART at higher CD4 cell counts than those who died with AIDS (34.5% vs 16.8%, respectively, received HAART for 4 of more years, P < 0.0001; 22.4% vs 7.8%. respectively, initiated HAART with CD4 cell counts of more than 350 cells/mu L, P < 0.001). Conclusions: Although overall death rates remained low through 2004, the proportion of deaths attributable to non-AIDS diseases increased and prominently included hepatic, cardiovascular, and pulmonary diseases, as well as non-AIDS malignancies. Longer time spent receiving HAART and higher CD4 cell counts at HAART initiation were associated with death from non-AIDS causes. CD4 cell count at time of death increased over time.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 35 条
[1]   A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].
Carr, A ;
Samaras, K ;
Burton, S ;
Law, M ;
Freund, J ;
Chisholm, DJ ;
Cooper, DA .
AIDS, 1998, 12 (07) :F51-F58
[2]   Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons [J].
Chung, RT ;
Andersen, J ;
Volberding, P ;
Robbins, GK ;
Liu, T ;
Sherman, KE ;
Peters, MG ;
Koziel, MJ ;
Bhan, AK ;
Alston, B ;
Colquhoun, D ;
Nevin, T ;
Harb, G ;
van der Horst, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) :451-459
[3]   Factors related to and consequences of adherence to antiretroviral therapy in an ambulatory HIV-infected patient cohort [J].
Deloria-Knoll, M ;
Chmiel, JS ;
Moorman, AC ;
Wood, KC ;
Holmberg, SD ;
Palella, FJ .
AIDS PATIENT CARE AND STDS, 2004, 18 (12) :721-727
[4]   Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis [J].
Detels, R ;
Tarwater, P ;
Phair, JP ;
Margolick, J ;
Riddler, SA ;
Muñoz, A .
AIDS, 2001, 15 (03) :347-355
[5]   Protease inhibitor-associated hyperglycaemia [J].
Dube, MP ;
Johnson, DL ;
Currier, JS ;
Leedom, JM .
LANCET, 1997, 350 (9079) :713-714
[6]  
ELSADR W, 13 C RETR OPP INF FE
[7]   Recent trends in HIV-related inpatient admissions 1996-2000 - A 7-state study [J].
Fleishman, JA ;
Hellinger, FH .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 (01) :102-110
[8]   Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome [J].
Grinspoon, S .
CLINICAL INFECTIOUS DISEASES, 2003, 37 :S85-S90
[9]   Protease inhibitors and cardiovascular outcomes in patients with HIV-1 [J].
Holmberg, SD ;
Moorman, AC ;
Williamson, JM ;
Tong, TC ;
Ward, DJ ;
Wood, KC ;
Greenberg, AE ;
Janssen, RS .
LANCET, 2002, 360 (9347) :1747-1748
[10]  
Kleinbaum DG., 1988, STUDENTS PARTIAL SOL, Vvol 601